SEARCH

SEARCH BY CITATION

References

  • 1
    Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306:118996.
  • 2
    Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94:5967.
  • 3
    Ishii K, Amagai M, Hall RP et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159:201017.
  • 4
    Mimouni D, Anhalt GJ. Pemphigus. Dermatol Ther 2002; 15:3628.
  • 5
    Stanley JR. Pemphigus. In: FreedbergIM, EisenAZ, WolffK et al., eds. Fitzpatrick's dermatology in general medicine, 5th edn. New York: McGraw-Hill, 1999:65466.
  • 6
    Vani J, Elluru S, Negi VS et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008; 7:4404.
  • 7
    Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the content of the magic draft IVIg? Autoimmun Rev 2008; 7:4359.
  • 8
    Krause I, Wu R, Sherer Y, Patanik M, Peter J, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations – a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002; 12:1339.
  • 9
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:74755.
  • 10
    Sultan Y, Kazatchkine MD, Maissoneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2:7658.
  • 11
    Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. J Clin Immunol 1998; 18:5260.
  • 12
    Evans MJ, Suenaga R, Abdou NI. Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin. J Clin Immunopathol 1991; 11:2915.
  • 13
    Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific IgG. J Immunol 1989; 143:41049.
  • 14
    Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83:298303.
  • 15
    Tandon N, Jayne DR, McGregor AM, Weetman AP. Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity. J Autoimmun 1992; 5:55770.
  • 16
    Lundkvist I, Van Doorn PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain–Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 1993; 67:1928.
  • 17
    Caccavo D, Vaccaro F, Ferri GM, Amoroso A, Bonomo L. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun 1994; 7:53748.
  • 18
    Mehta YS, Badakere SS. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins. J Postgrad Med 1996; 42:469.
  • 19
    DeKeyser F, DeKeyser H, Kazatchkine MD, Rossi F, Dang H, Talal N. Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol 1996; 14:58791.
  • 20
    Yuki N, Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci 1996; 139:1602.
  • 21
    Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 2004; 24:10714.
  • 22
    Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin – clinical and serological response. Lupus 1999; 8:70512.
  • 23
    Terryberry JF, Shoenfeld Y, Sherer Y et al. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations. Immunol Invest 2000; 29:33747.
  • 24
    Sherer Y, Wu R, Krause I, Peter JB, Shoenfeld Y. Antiphospholipid antibody levels in intravenous immunoglobulin (IVIG) preparations. Lupus 2001; 10:56870.
  • 25
    Silvestris F, Cafforio P, Dammacco F. Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol 1994; 97:1925.
  • 26
    Evans M, Abdou NI. In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin. Lupus 1993; 2:3715.
  • 27
    Mimouni D, Blank M, Ashkenazi L et al. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 2005; 142:42632.
  • 28
    Amagai M, Ikeda S, Shimizu H et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60:595603.
  • 29
    Payne AS, Ishii K, Kacir S et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005; 115:88899.
  • 30
    Payne AS, Siegel DL, Stanley JR. Targeting pemphigus autoantibodies through their heavy-chain variable region genes. J Invest Dermatol 2007; 127:168191.
  • 31
    Parham P. Preparation and purification of active fragments from mouse monoclonal antibodies. In: HerzenbergLA, WeirDM, BlackwellC, eds. Handbook of experimental immunology, vol 2. Oxford: Blackwell Scientific Publications, 1994:1435.
  • 32
    Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol 1996; 106:3515.
  • 33
    Cheng SW, Kobayashi M, Tanikawa A, Kinoshita-Kuroda K, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147:2615.
  • 34
    Rock B, Labib RS, Diaz LA. Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J Clin Invest 1990; 85:2969.
  • 35
    Anhalt GJ, Till GO, Diaz LA, Labib RS, Patel HP, Eaglstein NF. Defining the role of complement in experimental pemphigus vulgaris in mice. J Immunol 1986; 137:283540.
  • 36
    Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976; 67:25460.
  • 37
    Hashimoto K, Shafran KM, Webber PS, Lazarus GS, Singer KH. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. J Exp Med 1983; 157:25972.
  • 38
    Koch PJ, Mahoney MG, Ishikawa H et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997; 137:1091102.
  • 39
    Shimizu A, Ishiko A, Ota T, Tsunoda K, Amagai M, Nishikawa T. IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a pemphigus mouse model. J Invest Dermatol 2004; 122:114553.
  • 40
    Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol 1999; 112:6771.
  • 41
    Sato M, Aoyama Y, Kitajima Y. Assembly pathway of desmoglein 3 to desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy. Lab Invest 2000; 80:158392.
  • 42
    Calkins CC, Setzer SV, Jennings JM et al. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J Biol Chem 2006; 281:762334.
  • 43
    Shu E, Yamamoto Y, Sato-Nagai M, Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG reduces the desmoglein 3/desmocollin 3 ratio on the cell surface in cultured keratinocytes as revealed by double-staining immunoelectron microscopy. J Dermatol Sci 2005; 40:20911.
  • 44
    Demlehner MP, Schäfer S, Grund C, Franke WW. Continual assembly of half-desmosomal structures in the absence of cell contacts and their frustrated endocytosis: a coordinated Sisyphus cycle. J Cell Biol 1995; 131:74560.
  • 45
    Aoyama Y, Owada MK, Kitajima Y. A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur J Immunol 1999; 29:223340.
  • 46
    Caldelari R, De Bruin A, Baumann D et al. A central role for the armadillo protein plakoglobin in the autoimmune disease pemphigus vulgaris. J Cell Biol 2001; 153:82334.
  • 47
    Berkowitz P, Hu P, Liu Z et al. Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization. J Biol Chem 2005; 280:2377884.
  • 48
    Sánchez-Carpintero I, España A, Pelacho B et al. In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol 2004; 151:56570.
  • 49
    Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138:115862.
  • 50
    Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47:35863.
  • 51
    Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003; 13:37781.
  • 52
    Herzog S, Schmidt E, Goebeler M, Brocker EB, Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84:4852.
  • 53
    Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med 2004; 10:1718.
  • 54
    Blank M, Anafi L, Zandman-Goddard G et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007; 19:85765.
  • 55
    Blank M, Nur I, Toub O, Maor A, Shoenfeld Y. Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin Rev Allergy Immunol 2005; 29:21317.
  • 56
    Shoenfeld Y, Rauova L, Gilburd B et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14:130311.
  • 57
    Fuchs S, Feferman T, Meidler R et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol 2008; 194:8996.